Borrelia / Lyme disease ELISA Kit

Sample

Serum

Species Reactivity

Canine

Detection Method

iELISA

Intended Use

Borrelia / Lyme disease ELISA Kit is an enzyme immunoassay kit for the qualitative of Borrelia / Lyme disease of animals.

Contents of Kit

1. Antigen-coated microplate, 8 × 12 strips, 4°C. Unused strips should be sealed tightly in the air-tight pouch.
2. Control A (Negative Control), 2ml (Ready-to-use), 4°C
3. Control B (Cut-off Standard), 3ml (Ready-to-use), 4°C
4. Control C (Positive Control), 2ml (Ready-to-use), 4°C
5. HRP-Streptavidin solution, 20 ml (Ready-to-use), 4°C
6. Sample Diluent Buffer, 100 ml (Ready-to-use), 4°C
7. 20× Wash Buffer, 50 ml, 4°C
8. TMB Substrate, 15 ml (Ready-to-use), 4°C (Protect from light)
9. STOP Solution, 15 ml (Ready-to-use), 4°C
10. Plate sealer, 1 e.a., Room temperature

Storage

Store the unopened kit at 2-8 °C. Use the kit before expiration date.

Precision

The CV values of intra-assay precision is 5.6% and inter-assay precision is 8.1%.

Sensitivity

The sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analytic.
It is 95.00% (95% confidence interval: 75.13% - 99.87%)

General Description

Lyme disease, also known as Lyme borreliosis, is a vector-borne disease caused by the Borrelia bacterium, which is spread by ticks in the genus Ixodes. The most common sign of infection is an expanding red rash, known as erythema migrans (EM), which appears at the site of the tick bite about a week afterwards. The rash is typically neither itchy nor painful. Approximately 70–80% of infected people develop a rash. Early diagnosis can be difficult. Other early symptoms may include fever, headaches and tiredness. If untreated, symptoms may include loss of the ability to move one or both sides of the face, joint pains, severe headaches with neck stiffness or heart palpitations. Months to years later repeated episodes of joint pain and swelling may occur. Occasionally shooting pains or tingling in the arms and legs may develop. Despite appropriate treatment, about 10 to 20% of those affected develop joint pains, memory problems and tiredness for at least six months.